FUB-PB-22 is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.
FUB-PB-22 is a Anlage II controlled substance in Germany. It was scheduled in Japan in July 2014.
As of October 2015 FUB-PB-22 is a controlled substance in China.
It is also banned in Sweden.